Comparison of the Efficacy and Safety of a Doravirine-Based, Three-Drug Regimen in Treatment-Naïve HIV-1 Positive Adults: A Bayesian Network Meta-Analysis
Source : https://www.frontiersin.org/articles/10.3389/fphar.2022.676831/full
Introduction: Extensive use of antiretroviral therapy has remarkably improved the survival rates of people living with HIV. Doravirine (DOR) is a newly-approved antiretroviral belonging to the class of non-nucleoside reverse transcriptase inhibitors.
Conclusion: The network meta-analysis showed that DOR TDF 3TC/FTC has good efficacy and safety at 48 weeks.